Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.69 |
| ▸ | EDNRA | P25101 | 2/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284065 | 0.92 | AGTR2 (0.71) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL2280799 | 0.86 | AGTR2 (0.75) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL4301348 | 0.78 | AGTR2 (0.75) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL1458424 | 0.77 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL4773774 | 0.72 | EDNRA (1.00) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL4772943 | 0.72 | EDNRA (0.79) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL684147 | 0.72 | AGTR1 (1.00) | AGTR1LTB4R2ACHE | |
| SCHEMBL14414624 | 0.72 | EDNRA (0.75) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL25084344 | 0.71 | AGTR1 (0.70) | AGTR2EDNRAAGTR1LTB4R2ACHE | |
| SCHEMBL14414770 | 0.71 | EDNRA (0.74) | AGTR2EDNRAAGTR1LTB4R2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885EDNRA 10/4885AGTR1 1/4885 |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885EDNRA 10/4885AGTR1 1/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885EDNRA 10/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.